Understanding the internal diversity of transgender communities is essential for developing optimal, inclusive policies and service provision. To date, research on this topic remains scarce in Chile. We conducted a survey study describing sociodemographic characteristics (age, sex assigned at birth, onset age, nationality, education, sex work, having a partner, having children, sexual orientation, religiousness, gender identification, and gender affirmation pathways). A snowball sample of 377 self-identified transgender adults living in Chile (M = 31.88, range = 18-67) was collected for the purpose of this study. According to their sex assigned at birth, 139 participants were female and 238 male. Results revealed that sex assigned at birth was significantly associated with almost all the sociodemographic variables. Eight gender self-identification categories were obtained based on self-declaration. These gender identification categories varied according to sex assigned at birth. Finally, four patterns (clusters) of gender affirmative actions were identified among participants. These patterns indicated that the longer the gender affirmation pathway time, the greater the invasiveness level of the medical procedures used. Sex assigned at birth moderated the association between gender affirmation pathways and gender identity categories. Results were discussed highlighting the heterogeneity found in terms of sociodemographic characteristics, gender identification, and gender affirmation pathways.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10508-021-01939-4 | DOI Listing |
Transgend Health
December 2024
Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines.
View Article and Find Full Text PDFTransgend Health
December 2024
School of Teacher Education and Leadership, Utah State University, Logan, Utah, USA.
Purpose: In this article, we describe and illustrate the victimization experiences of transgender immigrants in the U.S. detention system.
View Article and Find Full Text PDFTransgend Health
December 2024
Child and Youth Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.
Purpose: This study describes Thai transfeminine individuals' exogenous hormone use.
Methods: During the period May-July 2017, a survey was conducted among Thai transfeminine adults (=181) who reported their exogenous hormone use, age at onset of use, brands used, where they obtained hormones, and discontinuation of use.
Results: Most participants (86.
Transgend Health
December 2024
Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Purpose: There is a paucity of data on the safety and efficacy of long-term testosterone (T)-based gender-affirming hormone therapy (GAHT) on anthropometric parameters, body composition, and glycolipid metabolism in assigned female at birth (AFAB) persons. The purpose of this study was to provide an updated meta-analysis on this topic.
Methods: We searched PubMed, Scopus, and Cochrane Library for relevant studies.
Transgend Health
December 2024
Fenway Health, The Fenway Institute, Boston, Massachusetts, USA.
Purpose: Transgender and nonbinary adults (TNB) are disproportionately burdened by sexually transmitted infections (STI) and the human immunodeficiency virus (HIV). This study investigated whether gender-affirming hormone therapy was associated with TNB adults' odds of screening for STI and HIV.
Methods: Longitudinal data came from the electronic medical records of TNB primary care patients receiving care at two community health centers located in Boston, Massachusetts, and New York City, New York, between January 2013 and December 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!